Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma.

Jaekyung CheonChanghoon YooJung Yong HongHan Sang KimDae-Won LeeMyung Ah LeeJin Won KimIlhwan KimSang-Bo OhJun-Eul HwangHong Jae ChonHo Yeong Lim

Published in: Liver international : official journal of the International Association for the Study of the Liver (2021)

Ate/Bev showed real-life efficacy and safety in Korean patients with advanced HCC, in line with results from phase III trial. Considering unfavourable survival outcomes of Ate/Bev in patients with elevated NLR, careful assessment of treatment response needs to be performed in this group.

Keyphrases

phase iii
open label
clinical trial
phase ii
double blind
placebo controlled
study protocol
metastatic colorectal cancer
randomized controlled trial